Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Kerwin

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
CNS Drugs|March 27, 2007
When should clozapine be initiated in schizophrenia?: Some arguments for and against earlier use of clozapineRobert Kerwin
Expert Opinion on Investigational Drugs|November 17, 2006
Discontinued drugs in 2005: schizophrenia drugsRobert Kerwin
Trends in Pharmacological Sciences|June 29, 2004
The National Institute for Clinical Excellence and its relevance to pharmacologyRobert Kerwin
Evidence-Based Mental Health|March 28, 2002
Olanzapine was more effective than lorazepam at 2 hours but not at 24 hours in bipolar mania with acute agitationRobert Kerwin
Journal of Psychopharmacology (Oxford, England)|March 3, 2007
The House of Commons Health Committee: 'The Influence of the Pharmaceutical Industry'. Too much too late?Robert Kerwin
JAMA|July 22, 2004
Suicide risk and the SSRIsSimon Wessely, Robert Kerwin
International Clinical Psychopharmacology|April 7, 2007
A controlled, mirror-image study of second-generation antipsychotics in the treatment of schizophreniaDavid Taylor, Karen Hayhurst, Robert Kerwin
Expert Opinion on Investigational Drugs|October 22, 2002
Developments in the pharmacological treatment of schizophreniaGina Kuperberg, Robert Kerwin, Robin Murray
International Journal of Psychiatry in Clinical Practice|June 14, 2014
A prescription survey of the use of atypical antipsychotics for hospital inpatients in the United KingdomD Taylor Shubhra Mace Shameem Mir Robert Kerwin
The British Journal of Psychiatry : the Journal of Mental Science|June 5, 2003
Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UKAndy Duggan, Juliet Warner, Martin Knapp, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
CNS Drugs|March 27, 2007
When should clozapine be initiated in schizophrenia?: Some arguments for and against earlier use of clozapineRobert Kerwin
Expert Opinion on Investigational Drugs|November 17, 2006
Discontinued drugs in 2005: schizophrenia drugsRobert Kerwin
Trends in Pharmacological Sciences|June 29, 2004
The National Institute for Clinical Excellence and its relevance to pharmacologyRobert Kerwin
Evidence-Based Mental Health|March 28, 2002
Olanzapine was more effective than lorazepam at 2 hours but not at 24 hours in bipolar mania with acute agitationRobert Kerwin
Journal of Psychopharmacology (Oxford, England)|March 3, 2007
The House of Commons Health Committee: 'The Influence of the Pharmaceutical Industry'. Too much too late?Robert Kerwin
JAMA|July 22, 2004
Suicide risk and the SSRIsSimon Wessely, Robert Kerwin
International Clinical Psychopharmacology|April 7, 2007
A controlled, mirror-image study of second-generation antipsychotics in the treatment of schizophreniaDavid Taylor, Karen Hayhurst, Robert Kerwin
Expert Opinion on Investigational Drugs|October 22, 2002
Developments in the pharmacological treatment of schizophreniaGina Kuperberg, Robert Kerwin, Robin Murray
International Journal of Psychiatry in Clinical Practice|June 14, 2014
A prescription survey of the use of atypical antipsychotics for hospital inpatients in the United KingdomD Taylor Shubhra Mace Shameem Mir Robert Kerwin
The British Journal of Psychiatry : the Journal of Mental Science|June 5, 2003
Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UKAndy Duggan, Juliet Warner, Martin Knapp, et al.
Pageof 2